patent for semaglutide Semaglutide's expires today. What does it mean patients, pharma players and Novo Nordisk? Synthesis method of semaglutide -

It was draining to say the least

Patients who might be considered for GLP-1 therapy (within licensed indications) and who may experience secondary benefits for binge eating behaviours include: Individuals with binge eating disorder and type 2 diabetes , where GLP-1 agonists address the primary diabetes indication whilst potentially helping with eating patterns Those with BED and obesity who meet NHS eligibility criteria for weight management medications (as defined by NICE TA875 for semaglutide or TA664 for liraglutide, which are narrower than the marketing authorisation) Patients who have not responded adequately to psychological interventions such as cognitive behavioural therapy (CBT) and who have concurrent metabolic conditions Those experiencing significant food cravings and loss-of-control eating as part of their weight management challenges However, important cautions and considerations apply

(fasting insulin, HOMA-IR a test that measures how resistant your body is to insulin C-peptide and proinsulin, both markers of insulin production)

Your success doesnt end when you stop the medication